食管癌组织β-微管蛋白Ⅲ表达与紫杉醇新辅助化疗疗效的关系  

Association of expression of β-tubulin Ⅲ with neoadjuvant chemotherapy efficacy of paelitaxel in advanced esophageal carcinoma

作　　者：叶振铭 陈碧茵[1] 吴瞿敏 

机构地区：[1]武警福建总队医院,福州350003

出　　处：《中华实验外科杂志》2015年第6期1432-1433,共2页Chinese Journal of Experimental Surgery

摘　　要：目的 探讨β-微管蛋白Ⅲ（TuBB3）在食管癌组织的表达与紫杉醇新辅助化疗疗效的关系.方法 应用免疫组织化学方法检测TUBB3蛋白在72例应用紫杉醇新辅助化疗的食管癌患者中的表达,分析化疗疗效、根治性手术切除率、术后分期、1年生存率.结果 TuBB3低表达组化疗有效率优于高表达组（68.4％比41.2％）,两组的手术切除率为94.6％和78.7％,术后分期降低率为62.2％和35.3％（T分期）、37.5％和15.6％（N分期）,术后1年生存率为89.2％和68.8％（P＜0.05）.结论 TuBB3蛋白可预测应用紫杉醇新辅助治疗食管癌的疗效,低表达者应用紫杉醇更能带来根治性手术切除率的提高及生存获益.Objective To explore the association of the expression levels of β-tubulin Ⅲ （TuBB3） in esophageal cancer with the neoadjuvant chemotherapy efficacy of paelitaxel.Methods The expression levels of TuBB3 were detected by immnohistochemistry.The association of the TuBB3 expression with the neoadjuvant chemotherapy efficacy of paelitaxel,the radical resection rate of tumor,the postoperative pathological staging and one-year survival rate was analyzed.Results The response rate of chemotherapy in the group with lower TuBB3 expression was higher than that with higher expression （68.4％ and 41.2％）.The group with lower TuBB3 also had higher radical resection rate of tumor （94.6％ and 78.7％）,lower postoperative pathological staging and higher one-year survival rate （89.2％ and 68.8％） than that with higher expression （P ＜ 0.05）.Conclusion TuBB3 can be a predictor for the efficacy of paelitaxel-based chemotherapy in the neoadjuvant treatment of esophageal cancer.Esophageal cancer patients with lowerl TuBB3 expression has higher radical resection rate of tumor,and more survival benefit postoperatively when treatment with paelitaxel.

关 键 词：食管癌 紫杉醇 β-微管蛋白Ⅲ 化疗 

分 类 号：R735.1[医药卫生—肿瘤]